Objectives: To explore the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and uric acid (UA) in acute ST-segment elevation myocardial infarction (STEMI) patients after complete revascularization (CR).

Methods: The clinical and physical data from 125 acute STEMI patients (research group) who underwent CR between December 2017 and December 2020 and 60 healthy individuals (control group) who concurrently underwent physical examinations in the Affiliated Hospital of Guizhou Medical University were retrospectively analyzed in this study. Serum samples were collected from both groups to determine the levels of NT-proBNP and UA. The 3-year follow-up data of acute STEMI patients were collected, which were used to group the patients into a good and a poor prognosis group based on their prognoses to comparatively analyze NT-proBNP and UA levels. Receiver operating characteristic (ROC) curves were drawn to analyze the prognostic value of NT-proBNP and UA in STEMI patients following CR, and survival curves were plotted to observe their influences on patients' 3-year overall survival (OS). Meanwhile, a univariate analysis was conducted to identify factors associated with the 3-year OS of acute STEMI patients after CR.

Results: The data showed significantly higher expression levels of serum NT-proBNP and UA in acute STEMI patients than in the controls. Besides, the good prognosis group exhibited markedly lower serum NT-proBNP and UA levels than the poor prognosis group. The areas under the curve (AUCs) of NT-proBNP and UA in predicting the prognosis of acute STEMI patients after CR were all above 0.700, and the AUC of their combined detection reached over 0.800. In addition, high serum NT-proBNP and UA levels were strongly associated with lower 3-year OS rates. As indicated by the univariate analysis, a history of smoking and alcoholism as well as high NT-proBNP and UA levels were closely associated with 3-year OS in acute STEMI patients after CR.

Conclusions: NT-proBNP and UA have promising prognostic value in acute STEMI after CR.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384352PMC
http://dx.doi.org/10.62347/VQWS9174DOI Listing

Publication Analysis

Top Keywords

stemi patients
32
acute stemi
28
nt-probnp levels
16
prognosis group
12
serum nt-probnp
12
patients
10
nt-probnp
10
acute
9
stemi
9
prognostic nt-probnp
8

Similar Publications

This review considers high-risk electrocardiographic patterns in the acute coronary syndrome (ACS) patient; we review 7 electrocardiogram presentations lacking diagnostic criteria for ST-segment elevation myocardial infarction (STEMI) yet likely representing either STEMI equivalent syndromes or ACS presentations with significant short-and long-term risk. The STEMI equivalent presentations include acute posterior wall myocardial infarction, the hyperacute T-wave of early STEMI, de Winter syndrome, first diagonal of the left anterior descending artery occlusion, and left bundle branch block modified Sgarbossa positive findings. High-risk presentation, not felt to be STEMI equivalent entities yet still possessing significant risk of short-and long-term adverse outcome, include lead aVR ST-segment elevation and Wellens syndrome.

View Article and Find Full Text PDF

Risk stratification of hospital mortality in patients with ST segment elevation myocardial infarction on the electrocardiogram is an important part of the specialized medical care provision. The systematic review presents scientific literature data characterizing the predictive value of both classical prognostic scales (GRACE, CADDILLAC, TIMI risk score for STEMI, RECORD, etc.) and new risk measurement tools developed on the basis of modern machine learning techniques.

View Article and Find Full Text PDF

Acute myocardial infarction (AMI) remains one of the most common causes for cardiogenic shock (CS), with high inpatient mortality (40-50 %). Studies have reported the use of pulmonary artery catheters (PACs) in decompensated heart failure, but contemporary data on their use to guide management of AMI-CS and in different SCAI stages of CS are lacking. We investigated the association of PACs and clinical outcomes in AMI-CS.

View Article and Find Full Text PDF

Tongxinluo capsules for secondary prevention after ST-segment elevation myocardial infarction: A systematic review and meta-analysis.

J Ethnopharmacol

January 2025

Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address:

Ethnopharmacological Relevance: Tongxinluo (TXL), a Chinese patent medicine, is commonly used for secondary prevention of cardiovascular events.

Aim Of The Study: To evaluate the efficacy and safety of TXL for secondary prevention after ST-segment elevation myocardial infarction (STEMI).

Materials And Methods: A search for relevant randomized controlled trials (RCTs) was conducted across seven electronic databases from inception to May 10, 2024.

View Article and Find Full Text PDF

Objective: Newly diagnosed AF (NOAF) associated with acute STEMI holds significant relevance in clinical practice. This study seeks to assess the role of the monocyte to HDL-C ratio (MHR) in predicting NOAF in these patients.

Methods: Between July 2017 and May 2018, 663 patients who underwent primary PCI for STEMI were retrospectively analyzed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!